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Summary
Background:  Renal  impairment  in  patients  with  coronary  artery  disease  (CAD)  is  common  and
increases  morbidity  and  mortality.  Estimation  of  glomerular  ﬁltration  rate  (GFR)  by  measuring
serum creatinine  (Cr)  or  Cr  clearance  has  limitations.  Cystatin  C  is  a  novel  marker  for  renal
function that  is  very  sensitive  and  speciﬁc  for  GFR  estimation.  The  utility  of  plasma  cystatin  C
(PCyC) in  patients  with  CAD  needs  further  study,  especially  in  the  developing  world,  where  CAD
is rising  exponentially.
Methods  and  results:  In  a  prospective  study  of  150  patients  undergoing  coronary  angiography,
median PCyC  was  1.45  mg/L;  patients  with  levels  ≥1.45  mg/L  were  older,  had  higher  mean
number of  diseased  coronary  vessels,  more  frequently  had  triple  vessel  disease  (TVD),  and
diffuse CAD  on  angiography.  This  association  of  higher  PCyC  levels  with  CAD  remained  robust
even after  excluding  patients  with  eGFR  <  60  ml/min/1.73  m2.  The  relative  risk  (RR)  of  having
TVD or  diffuse  CAD  in  the  overall  cohort  was  1.7  and  1.9,  while  it  was  1.91  and  2.3  respectively
in those  with  eGFR  ≥  60  ml/min/1.73  m2,  with  PCyC  levels  more  than  median.  Categorization
of the  entire  cohort  and  those  with  eGFR  ≥  60,  into  tertiles  based  on  33rd  and  66th  percentiles
of PCyC  maintained  the  association  of  cystatin  C  with  more  severe  CAD.
Conclusion:  In  Indian  patients  with  CAD,  higher  PCyC  levels  are  associated  with  more  severe
CAD. The  association  of  PCyC  with  severe  CAD  remains  robust  even  in  patients  with  normal  or
mildly impaired  renal  function.
for identiﬁcation  of  high  risk  CA
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Introduction
Concomitant  chronic  renal  impairment  (RI)  is  frequent
in  patients  with  cardiovascular  disease  and  substantially
increases  morbidity  and  mortality  [1—5]. Early  identiﬁcation
of  patients  with  RI  is  important  to  reliably  detect  high-risk
patients  and  institute  reno-protective  measures  whenever
required.  Traditionally,  RI  has  been  diagnosed  by  indirectly
calculating  glomerular  ﬁltration  rate  (GFR)  either  by  serum
creatinine  (Cr)  levels  or  estimation  of  creatinine  clearance
(CrCl)  by  Cockcroft-Gault  and  Modiﬁcation  of  Diet  in  Renal
Disease  (MDRD)  equations  [6,7]. However  assessment  of  GFR
using  these  has  several  limitations,  since  Cr  may  not  be
elevated  in  mild  RI,  while  CrCl  often  overestimates  true
GFR  [8].  Hence  a  more  sensitive  and  robust  marker  of  RI
is  required  in  clinical  practice.
Cystatin  C,  a  cysteine  protease  inhibitor,  has  been  pro-
posed  as  a  more  sensitive  and  speciﬁc  marker  for  detection
of  RI,  and  fulﬁlls  many  criteria  of  an  ideal  marker  of  GFR
[9].  It  is  less  inﬂuenced  by  age,  gender,  race,  muscle  mass,
and  medication,  as  compared  to  serum  Cr  and  is  sensitive
to  even  small  changes  in  GFR,  making  it  a  superior  marker
to  detect  mild  RI  which  may  not  be  detected  by  routine  Cr
measurements  [10,11].
Earlier  studies  have  shown  a  close  relationship  between
plasma  cystatin  C  (PCyC)  and  various  subsets  of  atheroscle-
rotic  disease  including  peripheral  as  well  as  coronary  artery
disease  (CAD),  both  with  stable  CAD  as  well  as  those  with
acute  coronary  syndromes  (ACS)  [12—16]. However,  a  few
studies  in  patients  with  CAD  have  failed  to  show  correlation
between  PCyC  with  CAD  and  atherosclerosis  [17—19]. Hence
the  clinical  utility  of  cystatin  C  in  patients  with  manifest
CAD,  especially  with  normal  or  only  mild  RI  merits  further
investigation.
Moreover  despite  the  increasing  trends  of  CAD  and  RI  in
the  developing  world,  scant  data  are  available  on  PCyC  lev-
els  and  its  predictive  value  in  patients  with  angiographically
proven  CAD  in  patients  of  Indian  origin.
Methods
Patients  with  suspected  or  proven  CAD  undergoing
coronary  angiography  at  our  institute,  were  included
in  this  cross-sectional  observational  study,  which  con-
formed  to  the  institutional  ethical  guidelines.  Patients
were  enrolled  in  the  study  with  prior  written  informed
consent;  all  patients  underwent  routine  biochemical
tests  prior  to  coronary  angiography,  while  PCyC  lev-
els  were  measured  using  particle-enhanced  nephelo-
metric  immunoassay  (PENIA)  method  (N  Latex  Cys-
C,  Dade  Behring,  Deerﬁeld,  IL,  USA).  The  estimated
(e)  GFR  was  calculated  from  MDRD  study  equation:
(ml/min/1.73  m2)  =  175  ×  (Scr)−1.154 ×  (Age)−0.203 ×  (0.742  if
female)  ×  (1.210  if  African  American).  Hypertension  (HT)
was  deﬁned  as  blood  pressure  ≥140/90  mmHg  or  having  a
history  of  antihypertensive  drug  use.  The  subjects  actively
inhaling  tobacco  smoke  in  any  form  were  considered  smok-
ers.  Diabetes  mellitus  (DM)  was  deﬁned  as  fasting  blood
glucose  level  ≥100  mg/dl  or  having  a  history  of  oral  hypo-
glycemic  drug  or  insulin  use.
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Patients  with  signiﬁcant  valvular  or  other  structural  heart
isease,  severe  symptomatic  heart  failure,  life-threatening
rrhythmias,  acute  and  chronic  liver  disease,  infectious,
uto-immune  and  chronic  inﬂammatory  disease,  cancers,
nd  on  any  form  of  renal  replacement  therapy,  were
xcluded.
All  patients  also  underwent  assessment  of  carotid  intimal
edial  thickness  (CIMT)  which  was  measured  as  per  standard
rotocol  with  10  MHz  linear  vascular  probe  on  GE  Vivid  7
imension  machine  (GE  Healthcare,  Chalfont  St  Giles,  UK).
he  carotid  segments  used  for  measurement  of  CIMT  were
he  distal  straight  1  cm  of  the  common  carotid  arteries,  the
arotid  bifurcations,  and  the  proximal  1  cm  of  the  internal
arotid  arteries.  The  average  of  measurements  taken  during
 cardiac  cycles  at  end-diastole  and  the  average  of  right  and
eft  CIMT  were  taken  as  the  mean  CIMT.
Coronary  angiography  was  performed  in  the  standard
anner  in  all  the  patients  through  either  radial  or  femoral
rtery  access.  Angiographic  analysis  was  done  by  stan-
ard  quantitative  angiographic  techniques  and  lesion  length
uantiﬁed  by  measuring  precisely  from  normal  to  normal
egment.  Angiographic  CAD  was  deﬁned  as  >50%  of  diame-
er  stenosis  in  any  of  the  major  epicardial  coronary  arteries,
hile  diffuse  CAD  was  deﬁned  as  involvement  of  >20  mm  seg-
ent  in  a  particular  epicardial  vessel.  For  exact  evaluation
f  a  tandem  lesion,  we  followed  the  principle  that  if  multi-
le  lesions  are  less  than  3  vessel  reference  diameters  apart
true  tandem  lesion),  these  lesions  would  be  scored  as  one
esion.
tatistical analysis
ll  the  data  were  analyzed  using  SPSS  .16  statistical  soft-
are  (SPSS  Inc.,  Chicago,  IL,  USA).  All  data  are  expressed
s  mean  ±  standard  deviation.  Student  t-test  was  used  to
ompare  means  between  groups,  and  the  chi-square  test
as  used  to  compare  proportions  between  groups.  Demo-
raphic  and  clinical  characteristics  were  compared  across  3
ategories  of  PCyC  level  with  analysis  of  variance  (ANOVA).
he  Pearson  correlation  was  used  to  analyze  the  correla-
ions  between  diffuse  CAD  with  cystatin  C  and  other  risk
actors;  p-value  less  than  0.05  was  considered  statistically
igniﬁcant.
esults
he  demographics  and  clinical  features  of  the  patient  popu-
ation  are  summarized  in  Table  1.  The  enrolled  150  patients
re  from  among  patients  undergoing  coronary  angiography
t  our  institute  from  the  period  of  October—December  2011.
f  166  patients  screened,  16  were  excluded  (11  due  to
eing  on  renal  replacement  therapy,  and  5  having  signiﬁcant
alvular  heart  disease).  The  mean  age  was  57.89  ±  9.43
ears  and  86%  were  males.  HT  was  present  in  53%,  DM  in
6%,  and  history  of  smoking  in  33%  of  cases.  Chronic  stable
ngina  was  noted  in  33%  while  a  history  of  ACS  (within  the
ast  4  weeks)  was  present  in  60%.  The  mean  serum  Cr  of
he  cohort  was  1.14  ±  0.56  (0.64—5.59)  mg/dl  while  mean
GFR  was  70.97  ±  18.86  (11.25—114.38)  ml/min/1.73  m2.
orty  of  one  hundred  and  ﬁfty  (26%)  patients  had  sig-
iﬁcant  renal  impairment  (eGFR  <  60  ml/min/1.73  m2);
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Table  1  Baseline  characteristics  of  the  entire  cohort  (150
patients).
Variables Mean  ±  SD  (N  =  150)
Age  (years)  57.89  ±  9.43
Sex  (M:F)  128:22
STEMI  [N(%)] 41  (27%)
USA/NSTEMI  [N(%)] 49  (33%)
CSA [N(%)] 49  (33%)
LVEF (%) 51.02  ±  10.89
TG  [mg%]  135.41  ±  58.04
TC [mg%]  135.40  ±  40.15
HDL  [mg%]  32.78  ±  8.73
LDL  [mg%]  75.44  ±  32.96
eGFR  (MDRD)  (ml/min/1.73  m2)  70.97  ±  18.86
Serum  creatinine  (mg/dl)  1.14  ±  0.56
CIMT (mean)  (mm)  0.63  ±  0.11
Cystatin  C  (mg/L)  1.8  ±  0.72
SVD [N(%)]  37  (24.5%)
DVD [N(%)]  35  (23.2%)
TVD [N(%)]  59  (39.1%)
No/Insigniﬁcant  disease  [N(%)]  20  (13.2%)
HT [N(%)]  80  (53%)
DM [N(%)]  54  (35.8%)
Smoker  [N(%)]  49  (32.7%)
Metabolic  syndrome  [N(%)]  90  (60%)
All values are expressed as mean ± SD.
STEMI, ST elevation myocardial infarction; USA, unstable angina;
NSTEMI, non ST-elevation myocardial infarction; CSA, chronic
stable angina; LVEF, left ventricle ejection fraction, as mea-
sured by echocardiography; TG, serum triglycerides; TC, serum
total cholesterol; HDL-C, high-density lipoprotein-cholesterol;
LDL-C, low-density lipoprotein-cholesterol; eGFR (MDRD), esti-
mated glomerular ﬁltration rate by 4 component Modiﬁcation
of Diet in Renal Disease formula; CIMT, carotid intima media
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Cthickness; SVD, single vessel disease; DVD, double vessel dis-
ease; TVD, triple vessel disease; HT, hypertension; DM, diabetes
mellitus.
f  these  37  had  eGFR  30—60  ml/min/1.73  m2 while
 had  eGFR  <  30  ml/min/1.73  m2.  Mean  PCyC  lev-
ls  were  1.8  ±  0.72  (0.51—6.87)  mg/L;  patients  with
GFR  <  60  ml/min/1.73  m2 had  signiﬁcantly  higher  mean
CyC  levels  (2.11  ±  1.11  mg/L)  as  compared  to  those  with
GFR  ≥  60  ml/min/1.73  m2 (1.36  ±  0.35  mg/dl,  p  <  0.001).
oronary  angiography  revealed  normal  coronary  anatomy
r  insigniﬁcant  CAD  in  13%,  while  single,  double,  and
riple  vessel  (TVD)  CAD  were  present  in  25%,  23%,  and  39%
espectively.  In  the  ﬁnal  analysis,  the  20  patients  with  no
igniﬁcant  CAD  were  excluded.
nalysis  of  the  entire  patient  cohort  according  to
ystatin  C  level
he  median  PCyC  levels  of  the  entire  cohort  was
.45  mg/L.  Categorizing  the  patients  into  two  groups
ccording  to  PCyC  levels  ≥/<1.45  mg/L  revealed  that
atients  with  higher  PCyC  levels  were  older  (60.3  ±  8.9
ears  vs.  55.4  ±  9.4  years,  p  <  0.001),  had  higher
erum  Cr  (1.32  ±  0.73  mg/dl  vs.  0.95  ±  0.16  mg/dl,
 <  0.001),  lower  eGFR  (61.59  +  18.97  ml/min/1.73  m2
h
(
o
iigure  1  Mean  number  of  diseased  coronary  vessels  involved
n different  groups.
s.  80.74  ±  12.91  ml/min/1.73  m2,  p  <  0.001),  and  higher
ean  CIMT  (0.64  +  0.11  mm  vs.  0.61  +  0.10  mm,  p  <  0.05)
Table  2).  Analysis  of  angiographic  severity  of  CAD  in  these
wo  subgroups  revealed  that  patients  with  higher  PCyC
evels  more  frequently  had  TVD  on  coronary  angiography
46%  vs.  32%,  p  =  0.07)  and  diffuse  angiographic  CAD  (69%
s.  54%,  p =  0.04).  The  mean  number  of  diseased  coronary
essels  demonstrated  a  trend  toward  being  higher  in
hose  with  PCyC  levels  ≥1.45  mg/dl  (2.03  ±  1.05  mg/dl
s.  1.73  ±  1.09  mg/dl),  though  this  was  of  only  borderline
tatistical  signiﬁcance  (p  =  0.06,  Fig.  1).  The  prevalence  of
T,  DM,  smoking  and  clinical  pattern  of  presentation  of  CAD
ere  similar  among  the  two  groups.
elative  risk  of  developing  TVD  or  diffuse  CAD
ccording to  PCyC  levels
mong  the  entire  patient  cohort,  patients  with
CyC  ≥  1.45  mg/dl  had  a 1.7  times  higher  relative  risk
RR)  of  having  TVD  (95%  CI  0.89—3.36)  and  a  1.9  times
igher  RR  of  having  diffuse  CAD  on  coronary  angiography
95%  CI  0.96—3.65,  p  =  0.04).
ivision  of  the  entire  patient  cohort  into  tertiles
ased on  33rd  and  66th  percentiles  of  PCyC  levels
e  observed  that  compared  to  patients  in  the  lower
wo  tertiles  (PCyC  <  1.32  mg/L  and  1.32—1.61  mg/L),
hose  in  the  highest  tertile  (PCyC  >  1.61  mg/L)  were
igniﬁcantly  older  (60.5  ±  9.1  years,  58.5  ±  9.2  years,
nd  54.8  ±  9.2  years,  respectively,  p  =  0.007)  (Table  3);
ad  higher  mean  serum  Cr  levels  (1.42  ±  0.88  mg/dl,
.06  ±  0.21  mg/dl,  and  0.94  ±  1.67  mg/dl,  respec-
ively,  p  =  0.001),  lower  mean  eGFR  (58.3  ±
9.5  ml/min/1.73  m2,  72.3  ±  16.3  ml/min/1.73  m2,  and
1.74  ±  12.3  ml/min/1.73  m2, respectively,  p  =  0.001),  and
igher  mean  CIMT  (0.65  ±  0.12  mm,  0.62  ±  0.11  mm,  and
.60  ±  0.09  mm,  respectively,  p  <  0.05).  The  incidence
f  HT,  DM,  smoking  and  mode  of  presentation  of  CAD
ere  similar  among  the  three  groups.  Coronary  angiog-
aphy  revealed  that  those  in  the  highest  PCyC  tertile
ad  signiﬁcantly  more  frequent  occurrence  of  diffuse
AD  (72%,  64%,  and  49%,  p  =  0.05),  and  a  trend  toward
aving  more  frequent  TVD  (48%,  37%,  and  32%,  p  =  0.07)
Fig.  2).  A  rising  trend  of  having  higher  mean  number
f  diseased  coronary  arteries  was  also  observed  in  those
n  the  highest  PCyC  tertile  (2.14  +  1.06,  1.88  +  1.06  and
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Table  2  Analysis  of  the  entire  patient  cohort  according  to  median  cystatin  C  levels.
Variables  Cystatin  C  <1.45  (mg/L)  Cystatin  C  ≥1.45  (mg/L)  p-Value
Age  (years)  55.4  ±  9.4  60.3  ±  8.9  0.001
Sex (M:F)  62:12  67:10  NS
STEMI [N(%)]  20  (27%)  21  (27.6%)  NS
USA/NSTEMI  [N(%)]  23  (31%)  26  (34.2%)  NS
CSA [N(%)] 24  (32.4%)  25  (32.9%)  NS
LVEF (%) 50.79  ±  11.5 51.24  ±  10.35 NS
Serum creatinine  (mg/dl) 0.95  ±  0.16 1.32  ±  0.73 <0.001
eGFR (MDRD)  (ml/min/1.73  m2) 80.74  ±  12.91 61.59  ±  18.97 <0.001
CIMT (mean)  (mm)  0.61  ±  0.10  0.64  ±  0.110  0.05
TVD [N(%)]  24  (32.4%)  35  (45.5%)  0.07
Diffuse CAD  [N(%)]  40  (54.1%)  53  (68.8%)  0.04
HT [N(%)] 35  (47.3%)  45  (58.4%)  NS
DM [N(%)]  26  (35.1%)  28  (36.4%)  NS
Smoker [N(%)]  26  (35.1%)  23  (30.3%)  NS
Metabolic syndrome  [N(%)]  46  (62.2%):28  (37.8%)  44  (57.1%):33  (42.9%)  NS
Mean no.  of  diseased  vessels  1.73  ±  1.09  2.03  ±  1.05  0.06
Values are expressed as mean ± SD.
STEMI, ST elevation myocardial infarction; USA, unstable angina; NSTEMI, non ST-elevation myocardial infarction; CSA, chronic stable
angina; LVEF, left ventricle ejection fraction, as measured by echocardiography; eGFR (MDRD), estimated glomerular ﬁltration rate by 4
component Modiﬁcation of Diet in Renal Disease formula; CIMT, carotid intima media thickness; TVD, triple vessel disease; CAD, coronary
1
t
l
l
m
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cartery disease; HT, hypertension; DM, diabetes mellitus.
1.74  +  1.07,  respectively),  though  this  did  not  achieve
statistical  signiﬁcance.  The  RR  of  developing  TVD  was
1.96  (95%  CI  0.88—4.35)  and  RR  of  having  diffuse  CAD
on  coronary  angiography  was  2.67  (95%  CI  1.18—6.06,
p  =  0.01)  in  those  in  the  highest  vs.  the  lowest  PCyC
tertile.
In  the  overall  cohort,  factors  predicting  diffuse  CAD
on  univariate  regression  analysis  included  diabetes  [odds
ratio  (OR)  3.68,  95%  CI  1.69—7.96,  p  <  0.001],  high-density
lipoprotein  cholesterol  (HDL-C)  levels  (OR  0.95,  95%  CI
0.91—0.98,  p  =  0.013)  and  PCyC  levels  (OR  1.65  95%  CI
l
p
H
Table  3  Comparison  of  three  tertiles  based  on  33rd  and  66th  per
Variables  Cystatin  C  <1.32  mg/L  Cyst
Age  (years) 54.8  ±  9.2 58.5
Sex (M:F) 45:8  41:7
LVEF (%) 49.9  ±  11.5 51.8
Serum creatinine  (mg/dl)  0.94  ±  1.67  1.06
eGFR (MDRD)  (ml/min/1.73  m2)  81.74  ±  12.3  72.3
CIMT (mean)  (mm)  0.60  ±  0.09  0.62
TVD [N(%)]  17  (32.1%)  18  (3
Diffuse CAD  [N(%)]  26  (49.1%)  31  (6
HT [N(%)]  22  (41.5%)  27  (5
DM [N(%)]  17  (32.1%)  21  (4
Smoker [N(%)]  19  (35.8%)  16  (3
Metabolic syndrome  [N(%)]  29  (54.7%)  30  (6
Mean no.  of  diseased  vessels  1.74  +  1.07  1.88
Values are expressed as mean ± SD.
LVEF, left ventricle ejection fraction, as measured by echocardiograph
ponent Modiﬁcation of Diet in Renal Disease formula; CIMT, carotid in
artery disease; HT, hypertension; DM, diabetes mellitus..09—2.48,  p  <  0.01).  Factors  predicting  diffuse  CAD  on  mul-
ivariate  regression  analysis  included  diabetes  and  PCyC
evels.  Importantly,  even  after  adjusting  for  diabetes,  PCyC
evels  remained  a  signiﬁcant  predictor  of  diffuse  CAD  on
ultivariate  regression  analysis  (OR  1.63,  95%  CI  1.06—2.51,
 =  0.027).
In  the  overall  patient  population,  a  signiﬁcant  positive
orrelation  was  observed  between  diffuse  CAD  and  PCyC
evels  (r  =  0.195,  p  =  0.016)  and  presence  of  DM  (r  =  0.277;
 =  0.001)  while  a  negative  correlation  was  observed  with
DL-C  levels  (r  =  −0.21;  p  =  0.01).
centiles  of  plasma  cystatin  C  levels  in  entire  cohort.
atin  C  1.32—1.61  mg/L  Cystatin  C  >1.61  mg/L  p-Value
 ±  9.2  60.5  ±  9.1  0.007
 43:7  NS
 ±  10.3  51.4  ±  10.7  NS
 ±  0.21  1.42  ±  0.88  <0.001
 ±  16.3  58.3  ±  19.5  <0.001
 ±  0.11  0.65  ±  0.12  0.05
7.5%)  24  (48%)  0.07
4.6%)  36  (72%)  0.05
6.3%)  31  (62%)  0.09
3.8)  16  (32%)  NS
3.3%)  14  (28.6%)  NS
2.5%)  31  (62%)  NS
 +  1.06  2.14  +  1.06  0.07
y; eGFR (MDRD), estimated glomerular ﬁltration rate by 4 com-
tima media thickness; TVD, triple vessel disease; CAD, coronary
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Table  4  Analysis  of  patients  with  eGFR  ≥  60  ml/min/1.73  m2 according  to  median  cystatin  C  levels  (n  =  110).
Variables  Cystatin  C  <1.36  mg/L  Cystatin  C  ≥1.36  mg/L  p-Value
Age  (years) 54.7  ±  9.3  57.89  ±  8.83  0.06
Sex (M:F)  46:10  50:5  NS
STEMI [N(%)] 17  (30.4%)  13  (23.6%)  NS
USA/NSTEMI  [N(%)] 19  (30.3%) 17  (30.9%)  NS
CSA [N(%)] 17  (30.4%) 22  (40.0%) NS
LVEF (%) 49.62  ±  11.36 53.41  ±  9.7 NS
Serum creatinine  (mg/dl) 0.92  ±  0.13 0.99  ±  0.12 0.004
eGFR (MDRD)  (ml/min/1.73  m2)  82.65  ±  10.87  77.03  ±  11.78  0.01
CIMT (mean)  (mm)  0.59  ±  0.10  0.62  ±  .10  NS
TVD [N(%)]  17  (30.4%)  25  (45.5%)  0.07
Diffuse CAD  [N(%)]  29  (51.8%)  39  (70.9%)  0.03
HT [N(%)] 23  (41.1%)  36  (65.5)  0.008
DM [N(%)]  19  (33.9%)  16  (29.1%)  NS
Smoker [N(%)]  18  (32.1%)  18  (32.7%)  NS
Metabolic syndrome  [N(%)]  31  (55.4%)  32  (58.2%)  NS
Mean no.  of  diseased  vessels  1.66  ±  1.1  2.04  ±  1.04  0.05
Values are expressed as mean ± SD.
STEMI, ST elevation myocardial infarction; USA, unstable angina; NSTEMI, non ST-elevation myocardial infarction; CSA, chronic stable
angina; LVEF, left ventricle ejection fraction, as measured by echocardiography; eGFR (MDRD), estimated glomerular ﬁltration rate by 4
component Modiﬁcation of Diet in Renal Disease formula; CIMT, carotid intima media thickness; TVD, triple vessel disease; CAD, coronary
artery disease; HT, hypertension; DM, diabetes mellitus.
Analysis  in  patients  with  eGFR  ≥  60  ml/min/1.73  m2
Normal  or  near  normal  renal  function  (eGFR  ≥  60  ml/min)
was  present  in  110/150  (74%)  patients;  the  median
PCyC  levels  in  these  patients  were  1.36  mg/L.  Cate-
gorizing  these  patients  into  two  groups  based  on  the
median  PCyC  levels  (≥/≤1.36  mg/L,  Table  4)  revealed  that
those  with  higher  PCyC  levels  had  signiﬁcantly  higher
serum  Cr  levels  (0.99  ±  0.12  mg/dl  vs.  0.92  ±  0.13  mg/dl,
p  <  0.004),  lower  eGFR  (77.03  ±  11.78  ml/min/1.73  m2 vs.
82.65  ±  10.87  ml/min/1.73  m2,  p  =  0.01)  and  more  fre-
quently  had  HT  (66%  vs.  41%,  p  =  0.008).  Similar  to  what  was
observed  in  the  overall  cohort,  even  among  these  patients
with  normal/near  normal  eGFR,  those  with  higher  PCyC
levels  had  signiﬁcantly  more  frequent  occurrence  of  dif-
fuse  angiographic  CAD  (71%  vs.  51%,  p  <  0.03)  and  a  trend
toward  having  more  frequent  occurrence  of  TVD  on  coronary
Figure  2  Triple  vessel  disease  (TVD,  %)  and  diffuse  coronary
artery  disease  (CAD,  %)  in  plasma  cystatin  C  (PCyC)  tertiles
(N =  150).
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tngiography  (46%  vs.  30%,  p  =  0.07).  The  mean  number  of  dis-
ased  coronary  vessels  was  also  signiﬁcantly  higher  in  those
ith  PCyC  levels  ≥1.36  mg/L  as  compared  to  those  with
ower  levels  (2.04  ±  1.04  vs.  1.66  ±  1.1,  p  =  0.05)  (Fig.  1).
he  incidence  of  DM,  smoking,  and  mode  of  clinical  presen-
ation  of  CAD  were  similar  in  the  two  groups.
R  of  developing  TVD  or  diffuse  CAD  according  to
CyC levels  in  those  with  normal/near  normal  eGFR
xcluding  patients  with  eGFR  <  60  ml/min/1.73  m2 not  only
reserved  but  enhanced  the  association  of  the  increased
R  of  angiographically  documented  TVD  (RR  1.91,  95%
I  0.88—4.16)  with  PCyC  ≥  1.36  mg/L.  The  RR  of  hav-
ng  diffuse  angiographically  documented  CAD  was  also
igher  as  compared  to  that  observed  in  the  overall
atient  cohort  (RR  of  2.3,  95%  CI  1.04—4.96,  p  =  0.03  with
CyC  ≥  1.36  mg/L).
ivision  of  the  patients  with  normal/near  normal
GFR into  tertiles  based  on  33rd  and  66th
ercentiles  of  PCyC  levels
ompared  to  patients  in  the  lower  two  tertiles  (i.e.
CyC  levels  <1.22  mg/L  and  1.22—1.5  mg/L),  those  in
he  highest  tertile  (i.e.  PCyC  >  1.5  mg/L)  had  higher
erum  Cr  levels  (1.01  ±  0.12  mg/dl,  0.96  ±  0.11  mg/dl,
nd  0.91  ±  0.14  mg/dl,  p  =  0.007)  and  lower  mean  eGFR
75.8  ±  11.4  ml/min/1.73  m2,  79.7  ±  11.2  ml/min/1.73  m2,
nd  84.2  ±  11.1  ml/min/1.73  m2, p  =  0.009)  (Table  5).  How-
ver  mean  age  and  CIMT  were  comparable  among  the  three
ertiles,  in  contrast  to  what  was  observed  during  analysis  of
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Table  5  Comparison  of  three  tertiles  based  on  33rd  and  66th  percentiles  of  plasma  cystatin  C  levels  in  patients  with  eGFR
(MDRD) ≥60  ml/min/1.73  m2 (n  =  110).
Variables  Cystatin  C  <1.22  (mg/L)  Cystatin  C  1.22—1.5  (mg/L)  Cystatin  C  >1.5  (mg/L)  p-Value
Age  (years) 53.9  ±  8.7  57.1  ±  9.5  57.7  ±  8.9  0.172
Sex (M:F) 29:6 35:6  32:3  0.557
LVEF (%)  [mean  ±  SD] 49.2  ±  12.3 51.4  ±  10.5 53.9  ±  8.8  0.183
Serum creatinine  (mg/dl) 0.91  ±  0.14 0.96  ±  0.11 1.01  ±  0.12 0.007
eGFR (MDRD)  (ml/min/1.73  m2)  84.2  ±  11.1 79.7  ±  11.2 75.8  ±  11.4 0.009
CIMT (mean)  (mm)  0.61  ±  0.11  0.60  ±  0.10  0.63  ±  0.10  NS
TVD [N(%)]  13  (31.7%)  13  (37.1%)  16  (45.7%)  0.06
Diffuse CAD  [N(%)]  19  (54.3%)  25  (61%)  24  (68.6%)  0.06
HT [N(%)]  14  (40%)  22  (53.7%)  23  (65.7%)  0.09
DM [N(%)]  11  (31.4%)  17  (41.5%)  7  (20%)  NS
Smoker [N(%)]  12  (34.3%)  13  (31.7%)  11  (31.4%)  NS
Metabolic syndrome  [N(%)]  19  (54.3%)  25  (61%)  19  (54.3%)  NS
Mean no.  of  diseased  vessels  1.76  +  1.04  1.80  +  1.15  2.01  +  1.05  NS
Values are expressed as mean ± SD.
LVEF, left ventricle ejection fraction, as measured by echocardiography; eGFR (MDRD), estimated glomerular ﬁltration rate by 4 com-
ponent Modiﬁcation of Diet in Renal Disease formula; CIMT, carotid in
artery disease; HT, hypertension; DM, diabetes mellitus.
the  entire  patient  cohort.  The  prevalence  of  HT,  DM,  smok-
ing,  and  clinical  pattern  of  presentation  of  CAD  were  similar
among  the  three  groups.  On  coronary  angiography,  those  in
the  highest  PCyC  tertile  had  a  trend  toward  more  frequent
occurrence  of  diffuse  CAD  (69%,  61%,  and  54%  respec-
tively)  as  well  as  TVD  (46%,  37%,  and  31%)  although  this
did  not  achieve  statistical  signiﬁcance  (Fig.  3).  There  was
also  a  trend  toward  having  higher  mean  number  of  diseased
coronary  arteries  among  those  in  the  highest  PCyC  ter-
tile  (2.01  +  1.05,  1.80  +  1.15,  and  1.76  +  1.04  respectively).
Even  in  patients  with  normal/near  normal  renal  function
(eGFR  ≥  60  ml/min/1.73  m2),  there  was  an  increased  RR  of
developing  TVD  as  well  as  diffuse  CAD  with  rising  PCyC  lev-
els  (RR  of  developing  TVD:  1.4,  95%  CI  0.55—3.7  and  RR  of
having  diffuse  CAD:  1.88,  95%  CI  0.69—4.87)  in  the  highest
vs.  the  lowest  PCyC  tertiles  respectively.
In  these  patients  with  near  normal  eGFR,  factors  predict-
ing  diffuse  CAD  on  univariate  regression  analysis  included
diabetes  (OR  4.59,  95%  CI  1.71—12.31,  p  =  0.003),  and  PCyC
levels  (OR  2.27,  95%  CI  1.04—4.97,  p  =  0.04).  Factors  predict-
ing  diffuse  CAD  on  multivariate  regression  analysis  included
DM  and  PCyC  levels.  Importantly,  even  after  adjusting  for
Figure  3  Triple  vessel  disease  (TVD,  %)  and  diffuse  coronary
artery  disease  (CAD,  %)  in  plasma  cystatin  C  (PCyC)  tertiles
(N =  110).
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M,  PCyC  levels  remained  a  signiﬁcant  predictor  of  diffuse
AD  on  multivariate  regression  analysis  [OR  =  2.69  (95%  CI
.16—6.21,  p  =  0.021)].
Similar  to  the  overall  patient  cohort,  a  signiﬁcant  posi-
ive  correlation  was  observed  between  diffuse  CAD  and  PCyC
evels  (r  =  0.196,  p  =  0.039)  and  DM  (r  =  0.301,  p  =  0.01).
iscussion
oncomitant  chronic  kidney  disease  in  patients  with  CAD
s  common  and  substantially  increases  the  morbidity  and
ortality.  Although  even  mild  RI  is  associated  with  an
ncreased  cardiovascular  risk,  due  to  the  nonlinear  rela-
ionship  between  Cr  levels  and  GFR,  Cr  is  unreliable  for
etecting  small  reductions  in  GFR  and  mild  RI  [1,10,20,21].
ystatin  C  is  novel  marker  for  renal  function  that  has  been
hown  to  be  more  sensitive  and  speciﬁc  for  GFR  estimation
han  Cr-based  formulas.  It  is  less  inﬂuenced  by  age,  gender,
ace,  drugs,  and  muscle  mass  as  compared  to  Cr  and  estima-
ion  of  PCyC  levels  is  known  to  be  a  better  indicator  of  mild
I  which  may  not  be  detectable  by  Cr  measurement  [11,22].
In  our  prospective  study  of  150  patients  undergoing  coro-
ary  angiography,  we  observed  that  patients  with  higher
bsolute  PCyC  levels  were  slightly  older,  had  higher  CIMT,
ore  frequently  had  angiographically  documented  TVD  and
iffuse  CAD  and  also  had  a  trend  toward  having  higher  mean
umber  of  diseased  coronary  vessels  as  compared  to  those
ith  lower  PCyC  levels.  This  association  of  higher  PCyC
evels  with  CAD  remained  robust  even  in  those  patients
ith  normal/near  normal  eGFR  (eGFR  >  60  ml/min/1.73  m2).
nterestingly,  in  these  patients  with  supposedly  normal
GFR,  those  with  PCyC  levels  higher  than  the  median
alue  had  signiﬁcantly  lower  eGFR  as  compared  to  those
ith  lower  PCyC  levels  (Figs.  4  and  5).  Among  patients
ith  normal/near  normal  renal  function  we  again  observed
hat  those  with  higher  absolute  PCyC  levels  had  more  fre-
uent  occurrence  of  TVD,  higher  prevalence  of  diffuse
188  
Figure  4  Mean  estimated  glomerular  ﬁltration  rate  (eGFR)
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in 110  patients  with  eGFR  (Modiﬁcation  of  Diet  in  Renal  Dis-
ase) ≥60  ml/min/1.73  m2 according  to  median  plasma  cystatin
 (PCyC)  levels.
ngiographic  CAD,  and  signiﬁcantly  higher  mean  number  of
iseased  coronary  vessels  as  compared  to  those  with  lower
CyC  levels.
nhanced  RR  of  angiographic  CAD  with  higher
bsolute PCyC  levels
n  the  overall  patient  cohort,  the  RR  of  having  TVD  and
iffuse  CAD  was  1.7  and  1.9  respectively,  in  those  with
igh  absolute  PCyC  levels.  Among  patients  with  normal/near
ormal  renal  function,  this  association  of  severe  CAD  with
igher  PCyC  levels  was  not  only  preserved,  but  was  further
nhanced  (RR  of  TVD  1.91,  RR  of  diffuse  CAD  2.3).
Previous  studies  have  also  shown  a  close  relationship
etween  cystatin  C  and  CAD  both  in  patients  with  stable
AD  as  well  as  those  with  ACS  and  ST  elevation  myocardial
nfarction  [14,16,23,24]. The  European  Society  of  Cardiol-
gy  has  recommended  the  use  of  cystatin  C  for  predicting
yocardial  infarction  and  long-term  mortality  in  patients
ith  non-ST  elevation  ACS  [25]. Elevated  levels  of  PCyC
ave  been  shown  to  be  superior  to  serum  Cr,  eGFR,  or
rCl  in  predicting  the  occurrence  and  severity  of  CAD  as
ell  as  cardiovascular  events  and  outcome  during  follow  up
13,23,24,26—28].  However  some  other  studies  have  failed
o  demonstrate  an  association  between  PCyC  levels  and  CAD
nd  atherosclerosis  [17—19].
igure  5  Mean  estimated  glomerular  ﬁltration  rate  (eGFR)  in
hree plasma  cystatin  C  (PCyC)  tertiles  based  on  33rd  and  66th
ercentiles  of  PCyC  levels  in  patients  with  eGFR  (Modiﬁcation
f Diet  in  Renal  Disease)  ≥60  ml/min/1.73  m2 (N  =  110).
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Categorization  of  the  entire  patient  cohort  as  well  as
hose  with  eGFR  >  60  ml/min/1.73  m2 into  tertiles  based  on
3rd  and  66th  percentiles  of  PCyC  revealed  that  expect-
dly,  patients  in  the  highest  cystatin  tertiles  had  signiﬁcantly
igher  mean  serum  Cr  and  lower  mean  eGFR  values.  The
oronary  angiography  proﬁle  was  also  worse  in  those  in  the
ighest  PCyC  tertile;  these  patients  had  higher  mean  num-
er  of  diseased  coronary  arteries,  more  frequent  occurrence
f  TVD,  and  more  frequent  presence  of  diffuse  CAD  as  com-
ared  to  those  in  the  lower  two  tertiles.
nhanced  RR  of  angiographic  CAD  within  PCyC
ertiles
imilar  to  the  trends  seen  with  higher  absolute  levels  of
CyC,  there  was  a  higher  RR  of  TVD  (1.96)  and  diffuse  CAD
2.67)  in  the  highest  vs.  the  lowest  PCyC  tertiles;  the  associ-
tion  of  severe  CAD  with  higher  PCyC  tertiles  was  preserved
n  those  with  normal/near  normal  renal  function  (RR  of  TVD
.4,  RR  of  diffuse  CAD  1.88).
A  rising  trend  of  more  severe  CAD  and  worse  clinical
utcomes  with  higher  PCyC  levels  has  been  reported  previ-
usly  [14,23,24,29]. In  patients  with  non-ST-elevation  ACS,
he  RR  of  death  during  follow  up  was  1.8,  3.2,  and  11.7
n  the  2nd,  3rd,  and  4th  quartiles  of  cystatin  C  compared
ith  the  lowest  quartile,  and  the  highest  risk  was  observed
n  those  with  levels  >1.25  mg/L  [14]. Koc  et  al.  [23]  in  a
tudy  of  94  stable  patients  with  CAD  reported  that  CAD
everity  score  increased  as  the  PCyC  quartile  increased
quartiles  <  0.65  mg/L,  0.65—0.82  mg/L,  0.83—99  mg/L,  and
1  mg/L).  Keller  et  al.  [29]  reported  that  across  the  spec-
rum  of  CAD,  patients  in  the  highest  cystatin  C  quartile  had  a
.87  fold  higher  risk  of  cardiovascular  death  as  compared  to
he  pooled  lower  quartiles.  Sekizuka  et  al.  [30]  also  reported
hat  serum  cystatin  C  was  signiﬁcantly  greater  in  multives-
el  CAD  and  suggested  that  PCyC  levels  may  be  considered  a
ovel  risk  factor  for  coronary  arteriosclerosis.  The  associa-
ion  of  cystatin  C  with  cardiovascular  risk  is  postulated  to  be
ue  to  either  direct  pathologic  effects,  or  due  to  heightened
nﬂammatory  state  and  clustering  with  other  risk  factors,
ll  leading  to  enhanced  vulnerability  of  the  atherosclerotic
laque  [13,31].  Whatever  be  the  mechanism,  our  study  also
upports  the  observation  that  higher  cystatin  C  levels  are
ssociated  with  more  severe  CAD,  even  in  the  patient  subset
ith  normal/near  normal  renal  function.
onclusion
igher  levels  of  cystatin  C  in  patients  with  more  severe  CAD
uggest  its  clinical  usefulness  as  a  potential  biomarker  for
dentiﬁcation  of  high  risk  CAD  patients.  Whether  this  would
ssume  further  importance  with  an  increasing  burden  of
oexisting  subclinical  chronic  kidney  disease  and  cardiovas-
ular  disease  as  the  patient  population  becomes  older,  needs
o  be  substantiated  in  larger  studies.
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